Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment Strategy for Rifampin-Susceptible Tuberculosis
Nicholas I. Paton, C S G Cousins, Celina Suresh, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 10, pp. 873-887
Open Access | Times Cited: 90

Showing 26-50 of 90 citing articles:

Post-tuberculosis lung disease: towards prevention, diagnosis, and care
Jamilah Meghji, Sara C. Auld, Gregory P. Bisson, et al.
The Lancet Respiratory Medicine (2025)
Closed Access
Tuberculosis disease among people with HIV: therapeutic advances
Vidya Mave, Mandar Paradkar, Francesca Conradie, et al.
The Lancet HIV (2025)
Closed Access
Prevalence, clinical reasons and associated factors of extended treatment duration for drug susceptible tuberculosis – a real-world experience
Chih-Yu Liu, Rou-Tsern Chen, Chin‐Chung Shu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Is shorter the solution for tuberculosis treatment?
Rosa María Blanca Herrera, Jennifer Furin
The Lancet Infectious Diseases (2025)
Closed Access
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial
Nicholas I. Paton, C S G Cousins, Intan Permata Sari, et al.
The Lancet Infectious Diseases (2025)
Open Access
Bedaquiline: what might the future hold?
Emily S Shaw, Neil G. Stoker, Jessica Potter, et al.
The Lancet Microbe (2024), pp. 100909-100909
Open Access | Times Cited: 3
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
Theresa Ryckman, Christopher Finn McQuaid, Ted Cohen, et al.
The Lancet Global Health (2024) Vol. 12, Iss. 10, pp. e1629-e1637
Open Access | Times Cited: 3
Resolution of tuberculosis blood RNA signatures fails to discriminate persistent sputum culture positivity after eight weeks of anti-tuberculous treatment
Claire Calderwood, Alvaro Sanchez Martinez, James Greenan-Barrett, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 5, pp. 2400457-2400457
Open Access | Times Cited: 3
Shortening Tuberculosis Treatment — A Strategic Retreat
Véronique Dartois, Eric J. Rubin
New England Journal of Medicine (2023) Vol. 388, Iss. 10, pp. 939-941
Closed Access | Times Cited: 8
The use of BPaL containing regimen in the MDR/PreXDR TB treatments in Thailand
Piamlarp Sangsayunh, Thanyanuch Sanchat, Charoen Chuchottaworn, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases (2023) Vol. 34, pp. 100408-100408
Open Access | Times Cited: 7
Assessing efficacy in non‐inferiority trials with non‐adherence to interventions: Are intention‐to‐treat and per‐protocol analyses fit for purpose?
Matthew Dodd, James R. Carpenter, JA Thompson, et al.
Statistics in Medicine (2024) Vol. 43, Iss. 12, pp. 2314-2331
Open Access | Times Cited: 2
Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis
Hyung‐Jun Kim, Ye Jin Lee, Myung Jin Song, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Emerging bedaquiline-resistant tuberculosis
Christoph Lange, Anca Vasiliù, Anna M. Mandalakas
The Lancet Microbe (2023) Vol. 4, Iss. 12, pp. e964-e965
Open Access | Times Cited: 6
Antibiotic lethality dictates mycobacterial infection outcomes
Alexander Jovanovic, Frederick K. Bright, Ahmad Sadeghi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies
Daniel S. Graciaa, Marcos Coutinho Schechter, Krystle B. Fetalvero, et al.
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 6, pp. 595-616
Open Access | Times Cited: 5
Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials?
Gail Brenda Cross, Jim O’Doherty, Christina C. Chang, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 4, pp. 1229-1238
Open Access | Times Cited: 5
More Tailored Approaches to Tuberculosis Treatment and Prevention
Chung Wung Bark, W. Henry Boom, Jennifer Furin
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 177-188
Open Access | Times Cited: 5
Standards for clinical trials for treating TB
Philipp du Cros, Jane Greig, J.-W. C. Alffenaar, et al.
The International Journal of Tuberculosis and Lung Disease (2023) Vol. 27, Iss. 12, pp. 885-898
Open Access | Times Cited: 4
New framework to define the spectrum of tuberculosis
Keertan Dheda, Giovanni Battista Migliori
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 6, pp. 426-428
Closed Access | Times Cited: 1
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles
Stephen H. Gillespie, Andrew R. DiNardo, Sophia B. Georghiou, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 9, pp. 100869-100869
Closed Access | Times Cited: 1
Exfoliated dermatitis and hepatitis to first line Anti-Tubercular Therapy with treatment of Drug-Sensitive Tuberculosis with second line Anti-Tubercular Therapy: a roller coaster ride
Sonam Spalgais, Ahmed Safwan M., Parul Mrigpuri, et al.
Chest Disease Reports (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Faster, higher, stronger: the evolution of clinical perspectives on pan-TB
Liang Fu, Guofang Deng, Hongzhou Lu
One Health & Implementation Research (2024) Vol. 4, Iss. 2, pp. 38-52
Open Access | Times Cited: 1
The association and interactions of malnutrition, micronutrients, and drug therapy in the management of tuberculosis
Muhammad Maaz, Muhammad Tauseef Sultan, Stanley I.R. Okoduwa, et al.
World Nutrition (2024) Vol. 15, Iss. 2, pp. 102-114
Open Access | Times Cited: 1
Single-gene transcripts for subclinical TB: an individual participant data meta-analysis
James Greenan-Barrett, Simon C. Mendelsohn, Thomas J. Scriba, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Percent of lung involved in disease on chest X-ray predicts unfavorable treatment outcome in pulmonary tuberculosis
Marwan Ghanem, Ratnam Srivastava, Yasha Ektefaie, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1

Scroll to top